The battle against infectious diseases is taking a high-tech turn with the recombinant vaccines market expected to skyrocket at a CAGR of 11.3% until 2027. This growth is fueled by the precision and safety offered by this groundbreaking technology.
The growth of the recombinant vaccines market is due to an increase in research and development activities, rising prevalence of infectious diseases, and higher rates of vaccination on a global scale.Read Full Report: https://www.fortunebusinessinsights.com/industry-reports/recombinant-vaccines-market-101935What are Recombinant Vaccines?Unlike traditional vaccines, which often use weakened or killed viruses or bacteria, recombinant vaccines use recombinant DNA technology. This involves inserting the desired antigen (the part of the pathogen that triggers an immune response) into a host cell, such as bacteria or yeast. The host cell then produces large quantities of the antigen, which can be purified and used to create the vaccine.Why are they special? This method offers several advantages: